Long-term results of a randomized controlled trial in childhood IgA nephropathy

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 6, 2011, Pages 1301-1307

  Kamei, Koichi ^a   Nakanishi, Koichi ^b   Ito, Shuichi ^a   Saito, Mari ^a   Sako, Mayumi ^a   Ishikura, Kenji ^c   Hataya, Hiroshi ^c   Honda, Masataka ^c   Iijima, Kazumoto ^d   Yoshikawa, Norishige ^b  

^a NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HEPARIN; PREDNISOLONE; WARFARIN;

ARTICLE; CHILD; CHILDHOOD DISEASE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; SCHOOL CHILD; SINGLE DRUG DOSE; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ANTICOAGULANTS; AZATHIOPRINE; CELL PROLIFERATION; CHILD; DIPYRIDAMOLE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS, IGA; HEPARIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; MALE; PREDNISOLONE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEINURIA; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 79958205956     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08630910     Document Type: Article

References (31)

1. Appel GB, Waldman M: The IgA nephropathy treatment dilemma. Kidney Int 69: 1939-1944, 2006
2. Barratt J, Feehally J: Treatment of IgA nephropathy. Kidney Int 69: 1934-1938, 2006
3. Yoshikawa N, Tanaka R, Iijima K: Pathophysiology and treatment of IgA nephropathy in children. Pediatr Nephrol 16: 446-457, 2001
4. Yoshikawa N, Ito H, Nakamura H: Prognostic indicators in childhood IgA nephropathy. Nephron 60: 60-67, 1992
5. Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M for the Japanese Pediatric IgA Nephropathy Treatment Group: A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol 10: 101-109, 1999
6. Churg J, Bernstein J, Glassock RJ: Renal Disease: Classification and Atlas of Glomerular Diseases, 2nd Ed., Tokyo, Japan, Igakushoin Medical Publishers, 1995, pp. 86-88
7. Schwartz GJ, Haycock GB, Edelmann CM Jr., Spitzer A: A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58: 259-263, 1976
8. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976
9. Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, Ito H for the Japanese Pediatric IgA NephropathyTreatment Study Group: Steroid treatment for severe childhood IgA nephropathy: A randomized controlled trial. Clin J Am Soc Nephrol 1: 511-517, 2006
10. Yoshikawa N, Nakanishi K, Ishikura K, Hataya H, Iijima K, Honda M, Japanese Pediatric IgA Nephropathy Treatment Study Group: Combination therapy with mizoribine for severe childhood IgA nephropathy: A pilot study. Pediatr Nephrol 23: 757-763, 2008
11. Nakanishi K, Yoshikawa N: Immunoglobulin A nephropathy. In: Pediatric Nephrology, 6th Ed., edited by Avner ED, Harmon WE, Niaudet P, Yoshikawa N, Heidelberg, New York, Springer, pp. 757-781, 2009
12. Wyatt RJ, Hogg RJ: Evidence-based assessment of treatment options for children with IgA nephropathies. Pediatr Nephrol 16: 156-167, 2001
13. D'Amico G: Natural History of Idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am J Kidney Dis 36: 227-237, 2000
14. Yata N, Nakanishi K, Shima Y, Togawa H, Obana M, Sako M, Nozu K, Tanaka R, Iijima K, Yoshikawa N: Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol 23: 905-912, 2008
15. Coppo R, D'Amico G: Factors predicting progression of IgA nephropathies. J Nephrol 18: 503-512, 2005
16. Praga M, Gutiérrez E, González E, Morales E, Hernández E: Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 14: 1578-1583, 2003
17. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linné T: IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18: 1880-1888, 2007
18. Rauta V, Finne P, Fagerudd J, Rosenlof K, Tornroth T, Gronhagen-Riska C: Factors associated with progression of IgA nephropathy are related to renal function: A model for estimating risk of progression in mild disease. Clin Nephrol 58: 85-94, 2002
19. Bartosik LP, Lajoie G, Sugar L, Cattran DC: Predicting progression in IgA nephropathy. Am J Kidney Dis 38: 728-735, 2001
20. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F: Corticosteroids in IgA nephropathy: A randomized controlled trial. Lancet 353: 883-887, 1999
21. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F: Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: 157-163, 2004
22. Manno C, Torres DD, Rossini M, Pesce F, Schena FP: Randomized controlled clinical trial of corticosteroids plus ACE inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24: 3694-3701, 2009
23. Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H: Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis 53: 26-32, 2009
24. Julian BA, Barker C: Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial. Contrib Nephrol 104: 198-206, 1993
25. Lai KN, Lai FM, Ho CP, Chan KW: Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: A long-term controlled trial. Clin Nephrol 26: 174-180, 1986
26. Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, Yanase T, Masutani K, Kubo M, Fujimi S: Controlled, prospective trial of steroid treatment in IgA nephropathy: A limitation of low-dose prednisolone therapy. Am J Kidney Dis 41: 972-983, 2003
27. Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, Okada N, Imai E, Hori M, Tsubakihara Y: Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 35: 194-201, 2000
28. Cheng J, Zhang X, Zhang W, He Q, Tao X, Chen J: Efficacy and safety of glucocorticoids therapy for IgA nephropathy: A meta-analysis of randomized controlled trials. Am J Nephrol 30: 315-322, 2009
29. Goumenos D, Ahuja M, Shortland JR, Brown CB: Can immunosuppressive drugs slow the progression of IgA nephropathy? Nephrol Dial Transplant 10: 1173-1181, 1995
30. Shima Y, Nakanishi K, Kamei K, Togawa H, Nozu K, Tanaka R, Sasaki S, Iijima K, Yoshikawa N: Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy. Nephrol Dial Transplant 26: 163-169, 2011
31. Nakanishi K, Iijima K, Ishikura K, Hataya H, Awazu M, Sako M, Honda M, Yoshikawa N, The Japanese Pediatric IgA Nephropathy Treatment Study Group: Efficacy and safety of lisinopril for mild childhood IgA nephropathy: A pilot study. Pediatr Nephrol 24: 845-849, 2009